ArticleAntimicrobial agents and chemotherapy2018
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Mutations in theMicrobiology spectrum · 2026Article
- Association of Antimicrobial Susceptibility with Treatment Response inPathogens (Basel, Switzerland) · 2025Article
- Effects of Thermal and Antibiotic Treatments on the Viral Accumulation of FcMV1 inJournal of fungi (Basel, Switzerland) · 2025Article
- The Drug Susceptibility of Non-Tuberculous Mycobacteria (NTM) in a Referral Hospital in Rome from 2018 to 2023.Microorganisms · 2024Article
- In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022.The Journal of antimicrobial chemotherapy · 2023Article
- Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.Scientific reports · 2023Article
- Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.Microbiology spectrum · 2023Article
- An Overview of Mycoviral Curing Strategies Used in Evaluating Fungal Host Fitness.Molecular biotechnology · 2023Review
- Targeted and efficient delivery of rifampicin to macrophages involved in non-tuberculous mycobacterial infectionNanoscale advances · 2023Article
- Additive Effects of Cyclic Peptide [R4W4] When Added Alongside Azithromycin and Rifampicin againstPathogens (Basel, Switzerland) · 2023Article
- Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020.Tuberculosis and respiratory diseases · 2023Article
- Diagnosis and Management of Pulmonary NTM with a Focus onMicroorganisms · 2022Review
- Variability ofAntibiotics (Basel, Switzerland) · 2022Review
- Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.Annals of medicine · 2022Article
- In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.BMC microbiology · 2022Article
- Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.Antimicrobial agents and chemotherapy · 2022Article
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.Clinical pharmacokinetics · 2021Review
- Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events inJournal of Korean medical science · 2020Article
- Outcome of shorter treatment duration in non-cavitary nodular bronchiectaticJournal of thoracic disease · 2020Article
- Rational Choice of Antibiotics and Media forFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Byoung Soo KwonDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Mi-Na KimDepartment of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.ORCID 0000-0002-4624-6925
Heungsup SungDepartment of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Younsuck KohDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Woo-Sung KimDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Jin-Woo SongDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Yeon-Mok OhDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Sang-Do LeeDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Sei Won LeeDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Jae-Seung LeeDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Chae-Man LimDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Chang-Min ChoiDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Jin-Won HuhDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Sang-Bum HongDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Sojung ParkDepartment of Pulmonary, Allergy, and Critical Care Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, South Korea.
Tae Sun ShimDivision of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Yong Pil Chong *Department of Infectious Diseases, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea drchong@amc.seoul.kr heathcliff6800@hanmail.net.
Kyung-Wook Jo *Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea drchong@amc.seoul.kr heathcliff6800@hanmail.net.
Ulsan College · KRHallym University Dongtan Sacred Heart Hospital · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although it is known that the
Indexed as
AdultAgedAnti-Bacterial AgentsEthambutolFemaleHumansLung DiseasesMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium avium ComplexRifampinTreatment OutcomeAnti-Bacterial AgentsEthambutolRifampinethambutolMICMycobacterium avium complexrifampintreatment outcome
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.